News

Investigators observed no new safety concerns, no cases of Alzheimer-related imaging abnormalities, and no notable changes in laboratory evaluations and EKG.

Steve Hughes, MD, chief medical officer at Avidity Biosciences, provided commentary on recently announced positive topline data for AOC 1044, an investigational agent for Duchenne muscular dystrophy.

Take a look at the conferences in neurology that NeurologyLive® will cover for news in 2024.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2024 that neurology health care professionals should keep their eyes on.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2023.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 29, 2023.

As part of NeurologyLive®'s Year in Review, take a look at the most-read news articles on our site in sleep disorders in 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2023, with insights from Sharon Cohen, MD, FRCPC; Robert A. Hauser, MD, MBA; Alberto Espay, MD, PhD; Carolina Ferreira Atuesta, MD, MSc; and Natalie Goedeker, CPNP. [LISTEN TIME: minutes]

As part of NeurologyLive®'s Year in Review, take a look at our most-watched expert interviews in multiple sclerosis in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in neuromuscular disorders in 2023.

These were the most-watched interviews with experts in headache and migraine that we conducted in 2023, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in multiple sclerosis in 2023.

The neurologist at Cleveland Clinic shared thoughts on a recently published study assessing the relationship between blood biomarkers and change in cognitive function and brain volumes in a cohort of professional fighters.

In 2023, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-watched interviews with key opinion leaders in neuromuscular disorders in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in movement disorders in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our top news articles in headache and migraine in 2023.

Here's some of what is coming soon to NeurologyLive® this week.

As part of NeurologyLive®'s Year in Review, take a look at our most-watched expert interviews in sleep disorders in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in epilepsy and seizure disorders in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in stroke and cerebrovascular disease in 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news stories in Alzheimer disease and dementia in 2023.

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Sami Khella, MD, professor of clinical neurology at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, shared his reaction to the approval of eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 22, 2023.

A new study revealed daytime continuous polysomnography as a reliable and easily accessible diagnostic tool for identifying narcolepsy type 1 among pediatric patients.

With the approval, eplontersen becomes the first approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy that can be self-administered via an autoinjector.

Researchers have successfully grown norepinephrine neurons from stem cells, which are critical for regulating various bodily functions, offering new insights into neurodegenerative diseases such as Alzheimer and Parkinson.